Transgenic Mouse, ICSI & IVF Core

项目总结/摘要-转基因小鼠、ICSI和IVF核心 在动物中引入外源基因或选择性敲除内源基因的能力是不可能的。 对基础和临床研究有着重要的意义。特别是，随着CRISPR/Cas的出现， 技术，体内基因调节的前所未有的机会已经出现。因此，转基因是一种 非常强大的工具，促进体内基因组编辑和转录调节，对于解剖 转录、信号和环境对疾病遗传基础的影响， 开发新的治疗干预策略。此外，小鼠配子操作，克隆 技术、干细胞衍生和培养是一系列技术， 研究机构，特别是那些侧重于生殖和发育生物学的研究机构。 在第一阶段，夏威夷大学的转基因小鼠，ICSI和IVF核心（TMII）在研究所， 生物生成研究所成立，并朝着成为 在十五年内独立支持，积累了大量的显微操作设备， 小鼠配子和胚胎培养，并招募有经验的研究人员为核心实验室工作。 第二阶段的资金加强并发展了COBRE中心，使其成为一个最先进的设施， 在提供高效和经济的转基因动物及相关产品方面有着出色的业绩记录， 包括CRISPR技术。这些服务提供给了哥伦比亚大学的COBRE教师， 全国各地的夏威夷研究人员和科学家。核心继续开发新基因 包括在靶向基因插入方面取得重大进展。 第三阶段COBRE应用的目标是增强和转变核心，使其成为一个自我管理的系统。 持续的资源实体。除了扩展核心服务外，我们会继续致力改善 这些服务的质量和交付以及加强和精简核心业务。核心也将 加强外联工作，注重教育和培训，将其作为获取新知识和技能的主要渠道， 大学层次的客户。我们将通过协调和统一我们的现有投资组合， 核心资源和服务与分子和细胞免疫学（MCI）核心。我们还旨在 通过利用其众多资源增加调查员队伍并使其多样化，加强核心收入基础 供品。具体而言，我们将扩大我们的外联活动，改善营销活动，并探索机会， 与其他COBRE、INBRE和IDEA-CTR机构的核心合作。

PROJECT SUMMARY/ABSTRACT – Transgenic Mouse, ICSI and IVF Core The ability to introduce foreign genes or to selectively knock out endogenous genes in animals is of tremendous importance for basic and clinical research. In particular, with the advent of CRISPR/Cas technology, unprecedented opportunities for in vivo gene modulations have arisen. As such, transgenesis is a very powerful tool facilitating in vivo genome editing and transcription modulation, essential to dissect transcriptional, signaling, and environmental influences on the genetic basis of diseases but also for the development of novel therapeutic intervention strategies. Furthermore, mouse gamete manipulation, cloning technology, stem cell derivation, and -culture are a series of techniques that are essential for many successful research institutes in particular those with a focus on reproductive and developmental biology. During Phase I, the University of Hawaii Transgenic Mouse, ICSI and IVF Core (TMII) at the Institute for Biogenesis Research was established and made significant progress towards the goal of becoming independently supported within fifteen years, accumulated a large array of equipment for micromanipulation of mouse gametes and embryo culture and recruited experienced researchers to staff the Core laboratory. Funding during Phase II strengthened and developed the COBRE Center into a state-of-the-art facility with an outstanding track record in providing efficient and economic access to transgenic animals and related technologies, including CRISPR technologies. The services were provided to COBRE faculty, University of Hawaii researchers and scientists around the country. The Core continued the development of novel gene delivery technology, including making significant progress on targeted gene insertion. The objective of this Phase III COBRE application is to enhance and transform the Core into a self- sustained resource entity. Besides expanding our Core services, we will continue to work on improving the quality and delivery of these services and on enhancing and streamlining core operations. The Core will also enhance its outreach and focus on education and training as principal conduits for the acquisition of new customers at the University level. We will diversify our existing portfolio by coordinating and harmonizing our Core resources and services with those of the Molecular and Cellular Immunology (MCI) Core. We also aim to strengthen the core revenue base by increasing and diversify the contingent of investigators utilizing its many offerings. Specifically, we will expand our outreach, improve marketing activities and explore opportunities for collaborations with cores from other COBRE, INBRE and IDeA-CTR institutions.